# Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients

> **NCT02396316** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 54 (actual)

## Conditions studied

- Glaucoma, Neovascular

## Interventions

- **DRUG:** Aflibercept (Eylea, BAY 86-5321)
- **DRUG:** Sham Injection

## Key facts

- **NCT ID:** NCT02396316
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-02
- **Primary completion:** 2016-06-16
- **Final completion:** 2016-09-06
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2017-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02396316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02396316, "Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02396316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*